AMAZE-lung: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

Non Small Cell Lung Cancer Clinical Trial

— AMAZE-lung  

Official title:

A Multicentre Single-arm Phase II Trial of Amivantamab, Lazertinib Plus Bevacizumab in Patients With EGFR-mutant Advanced NSCLC With Progression on Previous Third-generation EGFR-TKI

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05601973
• Other study ID #: ETOP 18-21
• Secondary ID: 2021-002337-42
• Status: Recruiting
• Phase: Phase 2
• Start date: March 27, 2023
• Est. completion date: September 30, 2026

Study information

• Verified date: April 2024
• Source: ETOP IBCSG Partners Foundation
• Contact: Heidi Roschitzki, PhD
• Phone: +41 31 511 94 00
• Email: heidi.roschitzki[@]etop.ibcsg.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

AMAZE-lung is a multicenter single-arm phase II trial. The protocol treatment consists of amivantamab, lazertinib and bevacizumab (Zirabev®), given in a three-weekly regimen. The primary objective of the trial is to assess the efficacy of amivantamab and bevacizumab added to continued treatment with the third-generation EGFR-TKI lazertinib, in patients with EGFR-mutant advanced NSCLC, who have been previously treated with a third-generation EGFR-TKI in order to provide data on treatment effect and sample size required for a future phase III trial.

In addition, the safety of the treatment combination will be evaluated.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: September 30, 2026
• Est. primary completion date: March 30, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically confirmed non-squamous NSCLC, stage IIIB/C (not amenable to radical therapy) or stage IV according to 8th TNM classification.

2. Presence of a sensitising EGFR-mutation (only patients with exon 19 deletion and/or L858R are eligible) and documentation of T790M status, tested locally by an accredited laboratory.

3. Radiologically confirmed disease progression on previous treatment with osimertinib or lazertinib.Treatment with osimertinib must have been stopped at least 8 days before enrolment.

4. Achieved objective clinical benefit from osimertinib or lazertinib treatment (e.g., documented PR/ CR or SD for =6 months while on osimertinib or lazertinib treatment).

5. Measurable disease as defined according to RECIST v1.1.

6. Age =18 years.

7. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

8. Life expectancy =12 weeks.

9. Adequate haematological function:

• Haemoglobin =100 g/L,

• Absolute neutrophil count (ANC) =1.5× 109/L,

• Platelet count =75× 109/L.

10. Adequate renal function:

• Serum creatinine <1.5× ULN and calculated (Cockcroft-Gault formula) or measured creatinine clearance >45 mL/min.

11. Adequate liver function:

• ALT and AST =3× ULN. If the patient has liver metastases, ALT and AST must be =5× ULN.

• Total bilirubin =1.5× ULN. Patients with Gilbert's syndrome are eligible if conjugated bilirubin is within normal limits.

12. Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative pregnancy test (b-human chorionic gonadotropin [b-hCG]) within 5 weeks before enrolment and within 3 days before the first dose of protocol treatment. Women of childbearing potential must use highly effective contraceptive methods.

13. Written IC for trial participation must be signed and dated by the patient and the investigator prior to any trial-related intervention.

Exclusion Criteria:

1. Patients with known small cell lung carcinoma (SCLC) transformation.

2. Patients with symptomatic brain metastases. Patients with asymptomatic or previously treated and stable brain metastases may participate in this study. Patients who have received definitive radiotherapy or surgery for symptomatic or unstable brain metastases and have been clinically stable and asymptomatic for at =2 weeks before enrolment are eligible, provided they have been either off corticosteroid treatment or are receiving low-dose corticosteroid treatment (=10 mg/day prednisone or equivalent) for at least 2 weeks prior to enrolment.

3. Patients with an active or past medical history of leptomeningeal disease.

4. Patients with untreated spinal cord compression. Patients who have been definitively treated with surgery or radiotherapy and have a stable neurological status for =2 weeks prior to enrolment are eligible provided they are off corticosteroid treatment or are receiving low-dose corticosteroid treatment =10 mg/day prednisone or equivalent.

5. Patients with unresolved adverse events (other than alopecia) from prior anticancer therapy that have not resolved to grade =1 or baseline.

6. Patients with positive hepatitis B (hepatitis B virus [HBV]) surface antigen (HBsAg) test.

7. Patients with positive hepatitis C antibody (anti-HCV) test.

8. Patients with other clinically active infectious liver disease.

9. Patients who are known positive for HIV, with one or more of the following:

• Receiving antiretroviral therapy (ART) that may interfere with study treatment

• CD4 count <350 at screening.

• AIDS-defining opportunistic infection within 6 months before enrolment.

• Not agreeing to start ART and be on ART >4 weeks plus having HIV viral load <400 copies/mL at end of 4-week period (to ensure ART is tolerated and HIV is under control).

10. Patients with active cardiovascular disease including, but not limited to:

• Medical history of deep vein thrombosis or pulmonary embolism within 1 month prior to enrolment or any of the following within 6 months prior to enrolment: Myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary/peripheral artery bypass graft, or any acute coronary syndrome.

• Prolonged corrected QTcF >470 msec, clinically-significant cardiac arrhythmia (e.g., atrial fibrillation with uncontrolled rate) or abnormalities in conduction or morphologiy of electrocardiogram (ECG) (e.g., complete left bundle branch block, third- or second-degree heart block, PR interval >250 msec), or electrophysiologic disease (eg, placement of implantable cardioverter defibrillator).

• Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years in first degree relatives or any concomitant medications known to prolong QT interval or induce TdP.

• Uncontrolled (persistent) hypertension: systolic blood pressure >160 mm Hg; diastolic blood pressure >100 mm Hg.

• Congestive heart failure (CHF), defined as New York Heart Association (NYHA) class III-IV or hospitalisation for CHF (any NYHA class) within 6 months before enrolment.

• An active or past medical history of pericarditis, pericardial effusion that is clinically unstable, or myocarditis.

• Pericardial effusion considered due to the disease under study is permitted if clinically stable at screening.

• Baseline LVEF either <50% or below the lower limit of normal (LLN) per institutional guidelines, as assessed by screening echocardiogram (ECHO) or multigated acquisition (MUGA) scan.

11. Patients with interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis.

12. Patients with a history of haemoptysis (=2.5 mL of bright red blood per episode) within 1 month prior to enrolment.

13. Patients with evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation).

14. Patients with current or recent (within 10 days before enrolment) use of aspirin (>325 mg/day) or treatment with dipyridamole, ticlopidine, clopidogrel, and clostazol.

15. Patients with current use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes that has not been stable for >2 weeks prior to enrolment.

• The use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or aPTT is within therapeutic limits (according to the medical standard of the enrolling institution) and the patient has been on a stable dose of anticoagulants for at least 2 weeks prior to enrolment.

• Prophylactic anticoagulation for the patency of venous access devices is allowed, provided the activity of the agent results in an INR <1.5× ULN and aPTT is within normal limits within 14 days prior to enrolment.

• Prophylactic use of low-molecular-weight heparin (i.e., enoxaparin 40 mg/day) is permitted.

16. Patients with serious, non-healing wound, active ulcer, or untreated bone fracture.

17. Patients who had a core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to enrolment.

18. Patients who had major surgery or significant traumatic injury within 28 days prior to enrolment.

19. Patients who had placement of a vascular access device within 2 days prior to prior to enrolment.

20. Patients with a history of abdominal or tracheoesophageal fistula or gastrointestinal perforation within 6 months prior to enrolment.

21. Patients with clinical signs of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding.

22. Patients with evidence of abdominal free air not explained by paracentesis or recent surgical procedure.

23. Patients with concurrent or prior malignancy other than the disease under study.

Some exceptions require consultation with the ETOP IBCSG Partners

24. Patients with uncontrolled illness, including but not limited to:

• Uncontrolled diabetes.

• Ongoing or active infection, or diagnosed or suspected viral infection.

• Active bleeding diathesis.

• Impaired oxygenation requiring continuous oxygen supplementation.

• Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated drug, or previous significant bowel resection

• Psychiatric illness, social situation, or any other circumstances that would limit compliance with study requirements.

• Any ophthalmologic condition that is clinically unstable.

25. History of hypersensitivity to either the drug substance or any excipients in amivantamab, lazertinib and/ or bevacizumab.

26. Prior chemotherapy for NSCLC.

27. Prior treatment with bevacizumab or another anti-angiogenic inhibitor.

28. Prior treatment with a MET/EGFR-targeting antibody.

29. Judgement by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.

30. Women who are pregnant or in the period of lactation.

31. Women of childbearing potential or men who are sexually active with a woman of childbearing potential, who are not willing to use at least one method of highly effective contraception while receiving protocol treatment and for at least 6 months after the last dose of protocol treatment.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non Small Cell Lung Cancer

Intervention

Drug:
• Amivantamab
Amivantamab is given at a fixed dose of 1750 mg (if baseline body weight is <80 kg) or 2100 mg (if baseline body weight is =80 kg), i.v. every 3 weeks, until disease progression, or intolerable toxicity.
• Lazertinib
Lazertinib is given at a dose of 240 mg, orally, once daily. Treatment with lazertinib continues until disease progression or intolerable toxicities.
• Zirabev
Bevacizumab (Zirabev®) is administered at a dose of 15mg/kg, i.v. every 3 weeks, until disease progression, or intolerable toxicity.

Locations

Country	Name	City	State
France	Chu Angers	Angers
France	Centre Hospitalier d'Avignon	Avignon
France	Centre Léon Bérard	Lyon
Italy	SS Antonio e Biagio e Cesare Arrigo Hospital	Alessandria
Italy	AO SM Misericorida Perugia	Perugia
Netherlands	Netherlands Cancer Institute (NKI)	Amsterdam
Singapore	National University Hospital	Singapore
Spain	Hospital Universitario de A Coruña	A Coruña
Spain	Hospital Universitario Alicante Dr Balmis ISABIAL	Alicante
Spain	ICO Badalona	Badalona
Spain	Vall d´Hebron University Hospital VHIO	Barcelona
Spain	Hospital Universitario Basurto	Bilbao
Spain	Catalan Institute of Oncology	L'Hospitalet De Llobregat
Spain	Hospital Universitario Fundación Jiménez Díaz	Madrid
Spain	Hospital clínico universitario de Valladolid	Valladolid
Switzerland	Istituto Oncologico della Svizzera Italiana	Bellinzona
Switzerland	Universitätsklinik für Medizinische Onkologie, Inselspital	Bern
Switzerland	HFR Fribourg	Fribourg
Switzerland	Hôpitaux universitaires de Genève (HUG)	Genève
Switzerland	Kantonsspital St. Gallen	Saint Gallen
United Kingdom	The Royal Marsden NHS Foundation Trust	London

Sponsors (2)

Lead Sponsor	Collaborator
ETOP IBCSG Partners Foundation	Janssen Pharmaceuticals

Countries where clinical trial is conducted

France,  Italy,  Netherlands,  Singapore,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of amivantamab and bevacizumab added to continued treatment with a third-generation EGFR-TKI (osimertinib or lazertinib)	The primary endpoint to assess the efficacy of amivantamab and bevacizumab added to continued treatment with a third-generation EGFR-TKI (osimertinib or lazertinib) is the objective response rate (ORR), investigator assessed, at 12 weeks according to RECIST v1.1. ORR is defined as the rate of patients, among all enrolled patients, that achieve a best overall response [complete response (CR) or partial response (PR)] across all post-enrolment tumour-assessment time-points.	from date of enrolment until 12 weeks of follow-up.
Secondary	To evaluate secondary measures of clinical efficacy including progression-free survival (PFS), overall survival (OS), duration of response (DoR), disease control rate (DCR).	Secondary endpoint: Duration of response (DoR)	from date of first documented objective response (CR or PR) to the date of first documented progression/relapse or death, assessed up to 24 months.
Secondary	To evaluate secondary measures of clinical efficacy including progression-free survival	Secondary endpoint: Progression-free survival (PFS) according to RECIST v1.1	time from enrolment date until documented progression or death or date of last tumour assessment (for patient without PFS), assessed up to 24 months
Secondary	To evaluate secondary measures of clinical efficacy including progression-free survival	Secondary endpoint: Disease control rate (DCR) according to RECIST v1.1 patients, among all enrolled patients, that achieve CR or PR or disease stabilisation at 12 weeks.	from date of enrolment until 12 weeks after enrolment.
Secondary	To evaluate secondary measures of clinical efficacy including progression-free survival	Secondary endpoint: Overall survival (OS)	from date of enrolment until death from any cause. Censoring will occur at the last follow-up date (appr. 24 months after FPI).
Secondary	Safety and tolerability of the treatment based on any reported adverse events (any-cause, treatment-related, AEs leading to dose interruptions, withdrawal of treatment, and death as well as severe, serious and selected adverse events) and deaths	Secondary endpoint: Safety and tolerability (CTCAE v5.0)	From first patient enrolled until last patient last visit (about 24 months after FPI).